Jeffrey S. Abrams

13.7k total citations · 1 hit paper
104 papers, 4.4k citations indexed

About

Jeffrey S. Abrams is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Jeffrey S. Abrams has authored 104 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 33 papers in Cancer Research and 18 papers in Genetics. Recurrent topics in Jeffrey S. Abrams's work include Breast Cancer Treatment Studies (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Cancer Treatment and Pharmacology (14 papers). Jeffrey S. Abrams is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Cancer Treatment and Pharmacology (14 papers). Jeffrey S. Abrams collaborates with scholars based in United States, Canada and Belgium. Jeffrey S. Abrams's co-authors include Edward L. Korn, Larry Norton, Hyman B. Muss, Martine Piccart, Boris Freidlin, Joseph L. Pater, Nicholas J. Robert, Kathleen I. Pritchard, Dongsheng Tu and Robert B. Livingston and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey S. Abrams

102 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

2005 818 citations Paul E. Goss, James N. Ingle et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey S. Abrams United States	33	2.2k	1.7k	1.3k	811	631	104	4.4k
Boštjan Šeruga Canada	34	4.4k 2.0×	1.6k 1.0×	786 0.6×	1.8k 2.3×	315 0.5×	124	7.4k
Deborah Collyar United States	22	1.7k 0.8×	1.7k 1.0×	682 0.5×	530 0.7×	304 0.5×	69	3.2k
Francesco Perrone Italy	38	3.6k 1.7×	870 0.5×	430 0.3×	1.8k 2.2×	520 0.8×	188	5.9k
Olivia Pagani Switzerland	42	3.4k 1.5×	1.8k 1.1×	1.3k 1.0×	1.5k 1.9×	795 1.3×	159	5.5k
Rachel A. Freedman United States	32	2.4k 1.1×	1.5k 0.9×	535 0.4×	822 1.0×	360 0.6×	186	4.0k
Peyman Hadji Germany	37	3.9k 1.8×	769 0.5×	1.2k 1.0×	936 1.2×	227 0.4×	167	5.8k
Marjanka K. Schmidt Netherlands	42	2.1k 0.9×	2.0k 1.2×	1.4k 1.2×	484 0.6×	307 0.5×	160	4.8k
Ismail Jatoi United States	33	2.4k 1.1×	1.9k 1.1×	1.1k 0.9×	449 0.6×	517 0.8×	141	4.5k
Martin D. Abeloff United States	41	3.1k 1.4×	1.8k 1.1×	710 0.6×	988 1.2×	446 0.7×	119	6.4k
Karen Gelmon Canada	18	2.1k 0.9×	1.9k 1.2×	1.0k 0.8×	705 0.9×	435 0.7×	29	4.2k

Countries citing papers authored by Jeffrey S. Abrams

Since Specialization

Citations

This map shows the geographic impact of Jeffrey S. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Abrams more than expected).

Fields of papers citing papers by Jeffrey S. Abrams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Abrams. The network helps show where Jeffrey S. Abrams may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Abrams. A scholar is included among the top collaborators of Jeffrey S. Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Abrams. Jeffrey S. Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abrams, Jeffrey S., Geoffrey S. Pitt, Olivier Elemento, & Jim W. Cheung. (2023). PHOSPHOLAMBAN MUTATION LEADING TO RECURRENT SHORT-COUPLED POLYMORPHIC VENTRICULAR TACHYCARDIA AND FIBRILLATION IN PATIENT WITHOUT APPARENT STRUCTURAL HEART DISEASE. Journal of the American College of Cardiology. 81(8). 2452–2452. 1 indexed citations

Abrams, Jeffrey S., Daniel Roybal, Alexander N. Katchman, et al.. (2020). Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding–deficient channels. JCI Insight. 5(19). 16 indexed citations

Katchman, Alexander N., Lin Yang, Sergey I. Zakharov, et al.. (2017). Proteolytic cleavage and PKA phosphorylation of α _1C subunit are not required for adrenergic regulation of Ca _V 1.2 in the heart. Proceedings of the National Academy of Sciences. 114(34). 9194–9199. 31 indexed citations

Abrams, Jeffrey S., Barbara A. Conley, Margaret Mooney, et al.. (2014). National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. American Society of Clinical Oncology Educational Book. 71–76. 122 indexed citations

Malik, Shakun, Richard Pazdur, Jeffrey S. Abrams, et al.. (2014). Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer. Journal of Thoracic Oncology. 9(10). 1443–1448. 18 indexed citations

Freidlin, Boris, et al.. (2013). Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. JNCI Journal of the National Cancer Institute. 105(22). 1677–1683. 101 indexed citations

Yabroff, K. Robin, et al.. (2012). Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro-Oncology. 14(3). 351–359. 71 indexed citations

Morrison, Joan L., et al.. (2007). Noxious Menu: Chemically Protected Insects in the Diet of Caracara cheriway (Northern Crested Caracara). Southeastern Naturalist. 6(1). 1–14. 4 indexed citations

Mariotto, Angela B., Eric J. Feuer, Linda C. Harlan, & Jeffrey S. Abrams. (2006). Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999. JNCI Monographs. 2006(36). 7–15. 49 indexed citations

10.

Goss, Paul E., James N. Ingle, Silvana Martino, et al.. (2005). Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. JNCI Journal of the National Cancer Institute. 97(17). 1262–1271. 818 indexed citations breakdown →

11.

Coleman, C. Norman, Paul E. Wallner, & Jeffrey S. Abrams. (2003). Inflammatory Breast Issue. JNCI Journal of the National Cancer Institute. 95(16). 1182–1183. 3 indexed citations

12.

Abrams, Jeffrey S.. (1998). North American Adjuvant Breast Cancer Trials. Recent results in cancer research. 152. 417–428. 7 indexed citations

13.

Abrams, Jeffrey S., D. Vena, Janet H. Baltz, et al.. (1995). Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.. Journal of Clinical Oncology. 13(8). 2056–2065. 111 indexed citations

14.

Christian, Michaele C., Mary S. McCabe, Edward L. Korn, et al.. (1995). The National Cancer Institute Audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. New England Journal of Medicine. 333(22). 1469–1475. 54 indexed citations

15.

Kornblith, Alice B., Donna Hollis, E Zuckerman, et al.. (1993). Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.. Journal of Clinical Oncology. 11(11). 2081–2089. 67 indexed citations

16.

Parnes, Howard L., Jeffrey S. Abrams, Nancy Tait, et al.. (1991). Phase I/II Study of Cyclophosphamide, Doxorubicin, Fluorouracil, and Leucovorin for Treatment of Metastatic Adenocarcinoma. JNCI Journal of the National Cancer Institute. 83(14). 1017–1020. 5 indexed citations

17.

Abrams, Jeffrey S., Anthony A. Rayner, P H Wiernik, et al.. (1990). High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 82(14). 1202–1206. 57 indexed citations

18.

Eisenberger, Mario A. & Jeffrey S. Abrams. (1988). Gonadotropin hormone - Releasing hormone analogs for the treatment of prostatic cancer. Drugs of today. 24(4). 241–248. 3 indexed citations

19.

Piccart, Martine, Jeffrey S. Abrams, P. Dodion, et al.. (1988). Intraperitoneal Chemotherapy With Cisplatin and Melphalan. JNCI Journal of the National Cancer Institute. 80(14). 1118–1124. 16 indexed citations

20.

Dodion, P., et al.. (1987). Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015). European Journal of Cancer and Clinical Oncology. 23(6). 837–842. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact